MeSH tree: D12.776.543.750.705
A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in patients with high-risk smoldering multiple myeloma, according to results from CAR-PRISM, a phase II ...
Apr 20, 2026
0
3
Antibody therapeutics are laboratory-made proteins designed to work like the body's natural antibodies. They are widely used to treat diseases such as cancer by binding to specific targets, including cancer cells or inflammatory ...
Apr 8, 2026
0
8
The application of CAR immunotherapies to neurodegenerative diseases is limited by major challenges due to the complex nature of these pathologies and the heterogeneity of harmful molecules to be treated. Nonetheless, and ...
Apr 8, 2026
0
3
Researchers at The University of Texas MD Anderson Cancer Center have discovered a new blood-based biomarker that can help identify and characterize asymptomatic people with Lynch Syndrome (LS) who are more susceptible to ...
Apr 7, 2026
0
3
Fibrosis is the body's way of patching up damage—a bit like fixing a pothole. When skin is cut or a muscle is injured, fibroblast cells rush in to make fibronectin and collagen, which are two major extracellular matrix proteins ...
Apr 2, 2026
0
5
Researchers at the Kennedy Institute of Rheumatology have found that physically resisting the formation of an immunological synapse actually promotes a stronger immune response. The findings could help explain how immune ...
Mar 12, 2026
0
8
T cell lymphomas are notoriously difficult to treat because immunotherapy, despite being one of the most effective therapies for treating cancer, can't easily distinguish cancerous T cells from healthy ones. Now, scientists ...
Mar 10, 2026
0
14
The new generation of Alzheimer's disease drugs—the first proven to change the course of the disease—typically extend independent living for patients by 10 months. Called monoclonal antibodies, they reduce the accumulation ...
Mar 5, 2026
0
126
Researchers at the Ribeirao Preto Blood Center and the Center for Cell-Based Therapy (CTC) conducted a study using the NK-92 cell line to test new models of chimeric antigen receptors (CARs) with specific costimulatory domains, ...
Feb 20, 2026
0
12
For many people diagnosed with cancer, treatment with immune checkpoint inhibitors (ICIs) has dramatically extended lives. Some of these treatments, such as Keytruda and Opdivo, have become familiar brand names. However, ...
Feb 20, 2026
0
7
